Dianthus Therapeutics Announces Positive Phase 2 Results for Claseprubart in Generalized Myasthenia Gravis; Data to Be Presented at 2025 AANEM Annual Meeting
Reuters
Oct 02
Dianthus <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces Positive Phase 2 Results for Claseprubart in Generalized Myasthenia Gravis; Data to Be Presented at 2025 AANEM Annual Meeting
Dianthus Therapeutics Inc., a clinical-stage biotechnology company, announced that topline results from the Phase 2 MaGic trial of claseprubart (DNTH103), an active C1s inhibitor, in patients with generalized Myasthenia Gravis will be presented at the American Association of Neuromuscular and Electromagnetic Medicine (AANEM) Annual Meeting, scheduled for October 29 to November 1, 2025, in San Francisco, California. The company also plans to present additional analyses from the trial and new preclinical data regarding upstream inhibition. An oral presentation of the trial results will be delivered by Dr. Pushpa Narayanaswami, and a virtual industry forum featuring an expert panel will follow. The presentations are intended to highlight the potential benefits of claseprubart in the treatment of generalized Myasthenia Gravis.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dianthus Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9538973-en) on October 02, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.